To the Editor:
Gout is common in people with chronic kidney disease (CKD) and its treatment is frequently suboptimal in this special population due to concerns over adverse events and/or efficacy of medications. There is controversy about the use of urate-lowering therapy (ULT) in those with CKD and lack of agreement about the dosing of allopurinol, the recommended first-line ULT1,2. The aim of this study was to determine real-world ULT prescribing patterns among a group of medical practitioners with an interest in gout.
Members of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) were invited to participate in an online survey in May 2017. G-CAN is a multidisciplinary group (predominantly rheumatologists) with clinical/research interest in gout and crystalline arthritis. Ethical approval was not required for a professional online survey. Participants were asked for each stage of CKD …
Address correspondence to Prof. L. Stamp, Department of Medicine, University of Otago Christchurch, PO Box 4345, Christchurch 8140, New Zealand. Email: Lisa.Stamp{at}cdhb.health.nz.